about
Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatmentPrognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysisNeutrophils and Granulocytic MDSC: The Janus God of Cancer ImmunotherapyThe Multifaceted Roles Neutrophils Play in the Tumor MicroenvironmentActivation state of stromal inflammatory cells in murine metastatic pancreatic adenocarcinomaSequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8.Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiationSignificance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancerPre-treatment neutrophil to lymphocyte ratio predicts the chemoradiotherapy outcome and survival in patients with oral squamous cell carcinoma: a retrospective studyThe neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis.Association of the Preoperative Neutrophil-to-ymphocyte Count Ratio and Platelet-to-Lymphocyte Count Ratio with Clinicopathological Characteristics in Patients with Papillary Thyroid Cancer.Elevated preoperative neutrophil-to-lymphocyte ratio is associated with poor prognosis in gastrointestinal stromal tumor patients.Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy.Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy.Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors.Roles of preoperative C-reactive protein are more relevant in buccal cancer than other subsites.Causes of variation in the neutrophil-lymphocyte and platelet-lymphocyte ratios: a twin-family study.Neutrophils: important contributors to tumor progression and metastasis.Standardized pretreatment inflammatory laboratory markers and calculated ratios in patients with oral squamous cell carcinoma.Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer.Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients.Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients.Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma.A prognostic scoring system using inflammatory response biomarkers in oral cavity squamous cell carcinoma patients who underwent surgery-based treatment.The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma.Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer.Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer.Outcomes prediction in pre-operative radiotherapy locally advanced rectal cancer: leucocyte assessment as immune biomarker.Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
P2860
Q21328704-9636E1A5-D674-4300-A654-F053336BA70FQ27022482-25997D2B-9617-448A-8691-28329B463CE6Q28069360-B8EE4C88-760D-4DE2-A2A4-0E89BAD49F18Q28241308-5B82E1E3-092C-4FFF-9518-12F1FC875242Q33816747-F84BE31E-D6E6-4515-B62E-164A5320963DQ34111796-21B4864E-A3AD-4841-8CC3-DD9D07C82FA5Q34989484-C7997680-62C8-4AAF-A477-0AFB10D98FB9Q35651537-D82A755D-98BB-4C31-BB60-110A447B6D7AQ35905137-24EA397D-766C-4824-8FEB-224F999893D5Q36120942-AFB575B5-362D-4F14-BE0A-CB7407FFF3F0Q36489138-B8E7689F-2CFF-4C9B-B402-28CA6141764FQ36627492-AF6A57CE-600D-4009-BAA8-C0C13FF3846FQ36759598-A28819D9-E7CD-4765-A2F5-D413FC8A8696Q37223578-356B5931-7420-46BA-95A1-8C52BC6EC115Q37646545-C17747FB-1B13-4FC8-85CC-722947EB97FCQ37649049-8601BF44-2C81-4664-999E-CAA86A846A8BQ38377017-438A120D-6C3B-41FA-BC6D-4F98B312A359Q38585102-16DE71E0-BE0C-42E1-9441-FA0CE39541E2Q38901921-2B21C69A-2262-495D-AC66-E4CC83047F80Q39985070-9582B07A-64A7-46F1-8ABB-0CC826A21AACQ40877283-8E98F506-0279-4966-B5CE-75599F8796A8Q41259916-71A52CBC-ECE5-4EA6-BE5E-B9EA2D2D9273Q44317228-C4206206-9AF9-49B9-B69C-7F8BD3249B12Q47424577-7AD87DA1-9138-456D-8623-13CFDEA34C6CQ50158378-B57D68F2-3A76-4BE7-B4BD-AFF3D21AAFD7Q51039765-8C7DFA8A-A6FD-43E9-A7DF-3F19F8F5E4E1Q53071911-BA72C80B-C183-4A54-9135-4ACF631AF761Q53244866-26537897-344C-4216-B474-92BB46E6A57CQ55121878-838B71D9-ED89-4F4F-BBFB-C94450E9E88FQ55461245-E036163D-3146-4951-B03A-A35B60296FF9
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Neutrophils in the antitumoral immune response.
@ast
Neutrophils in the antitumoral immune response.
@en
type
label
Neutrophils in the antitumoral immune response.
@ast
Neutrophils in the antitumoral immune response.
@en
prefLabel
Neutrophils in the antitumoral immune response.
@ast
Neutrophils in the antitumoral immune response.
@en
P2093
P356
P1476
Neutrophils in the antitumoral immune response.
@en
P2093
P304
P356
10.1159/000071561
P577
2003-01-01T00:00:00Z